首页> 美国卫生研究院文献>Journal of Alternative and Complementary Medicine >Herbal Drug Regulation and Commercialization: An Indian Industry Perspective
【2h】

Herbal Drug Regulation and Commercialization: An Indian Industry Perspective

机译:草药管制和商业化:印度工业的观点

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Objectives: To assess the constraints for Indian herbal drug industry with respect to manufacturing and commercialization of herbal medicines.>Methods: A questionnaire-based survey was conducted to obtain primary data on challenges faced during production, commercialization, and marketing approval for traditional or herbal drugs in India and abroad. Responses were collected from 150 companies by email, telephone, and in-person interviews from June 2009 to August 2010 and were analyzed to draw appropriate conclusions.>Results: The survey result showed that differing regulatory requirements and the limited market in foreign countries are the major hindrances for exporting. Standardization and quality control of raw materials and herbal formulations emerged as the major challenge for Indian herbal drug manufacturing firms. Insufficient regulatory guidelines, particularly guidelines for good manufacturing practices; nonimplementation of good agricultural and collection practices; and weak implementation of the Drugs and Cosmetics Act of 1940 are considered major drawbacks for the Indian herbal industry.>Conclusions: Proper implementation of the Drugs and Cosmetics Act of 1940, development of more elaborate guidelines on quality control aspects, and development of marker-based standards are needed to produce safe and effective herbal medicines in India. Because evidence-based studies are becoming increasingly essential for establishing the safety and efficacy of herbal products in the domestic and export market, more focus should be placed on scientific and technological advancement in the field of herbal medicine. Regulatory harmonization becomes essential to mitigate the delays in commercialization across countries.
机译:>目标:评估印度草药行业在草药生产和商业化方面的制约因素。>方法:进行了基于问卷的调查,以获取有关挑战的主要数据在印度和国外对传统或草药的生产,商业化和市场批准过程中面临的挑战。从2009年6月至2010年8月,通过电子邮件,电话和面对面访谈从150家公司收集了反馈,并进行了分析,得出了适当的结论。>结果:调查结果表明,不同的监管要求和局限性国外市场是出口的主要障碍。原料和草药配方的标准化和质量控制已成为印度草药生产商的主要挑战。监管指南不足,尤其是良好生产规范指南;不执行良好的农业和收集规范;和1940年《药品和化妆品法案》的执行不力被认为是印度草药行业的主要弊端。>结论:正确实施1940年《药品和化妆品法案》,就质量控制方面制定了更为详尽的指南,并且需要开发基于标记的标准,以在印度生产安全有效的草药。由于基于证据的研究对于确立草药产品在国内和出口市场的安全性和有效性变得越来越重要,因此应将更多的注意力放在草药领域的科学和技术发展上。监管协调对于减轻各国之间的商业化延误至关重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号